Amori RE, Lau J and Pittas AG, ‘Efficacy and Safety of Incretin Therapy in Type 2 Diabetes’ (2007) 298 JAMA
Amy Kennedy, ‘Does Exercise Improve Glycaemic Control in Type 1 Diabetes? A Systematic Review and Meta-Analysis’ (2013) 8 PLoS ONE <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598953/>
Anderson B, Funnell M, and American Diabetes Association, The Art of Empowerment: Stories and Strategies for Diabetes Educators (2nd ed, American Diabetes Association 2005)
Anthony H. Barnett, Jenny Grice, New Mechanisms in Glucose Control (BMJ Books; 1 edition 2013) <http://ezproxy.lib.le.ac.uk/login?url=http://lib.myilibrary.com?id=478133>
‘[ARCHIVED CONTENT] Medicines Management: Everybody’s Business : Department of Health - Publications and Statistics’ <http://webarchive.nationalarchives.gov.uk/20080205142458/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_082200>
Ashwell SG and others, ‘Improved Glycaemic Control with Insulin Glargine plus Insulin Lispro: A Multicentre, Randomized, Cross-over Trial in People with Type 1 Diabetes’ (2006) 23 Diabetic Medicine 285
Atkinson MA, ‘The Pathogenesis and Natural History of Type 1 Diabetes’ (2012) 2 Cold Spring Harbor Perspectives in Medicine a007641
Avery L and others, ‘Changing Physical Activity Behavior in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Behavioral Interventions’ (2012) 35 Diabetes Care 2681
Bailey CJ and others, ‘Effect of Dapagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control with Metformin: A Randomised, Double-Blind, Placebo-Controlled Trial’ (2010) 375 The Lancet 2223
Barry VW and others, ‘Fitness vs. Fatness on All-Cause Mortality: A Meta-Analysis’ (2014) 56 Progress in Cardiovascular Diseases 382
Bennett WL and others, ‘Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations’ (2011) 154 Annals of Internal Medicine
Bethel MA and others, ‘Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS)’ [2017] Diabetes Care
Beverley M Shields, ‘Can Clinical Features Be Used to Differentiate Type 1 from Type 2 Diabetes? A Systematic Review of the Literature’ (2015) 5 BMJ Open <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636628/?report=classic>
Birkeland KI, ‘Hyperglycaemia in Pregnancy: Still a Lot to Learn’ (2015) 3 The Lancet Diabetes & Endocrinology 752
Bretzel RG and others, ‘Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO): An Open Randomised Controlled Trial’ (2008) 371 The Lancet 1073
Brown J and others, ‘Lifestyle Interventions for the Treatment of Women with Gestational Diabetes’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD011970.pub2>
Buse JB and others, ‘Liraglutide Once a Day versus Exenatide Twice a Day for Type 2 Diabetes: A 26-Week Randomised, Parallel-Group, Multinational, Open-Label Trial (LEAD-6)’ (2009) 374 The Lancet 39
Buse JB and others, ‘DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks’ (2010) 33 Diabetes Care 1255
Buse JB and others, ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’ (2011) 154 Annals of Internal Medicine
Capehorn M and others, ‘Challenges Faced by Physicians When Discussing the Type 2 Diabetes Diagnosis with Patients: Insights from a Cross-National Study (IntroDia )’ [2017] Diabetic Medicine
Carver C, ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’ (2006) 32 The Diabetes Educator 910
Celia G. Walker, ‘Modelling the Interplay between Lifestyle Factors and Genetic Predisposition on Markers of Type 2 Diabetes Mellitus Risk’ (2015) 10 PLoS ONE <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496090/>
Chatterjee S and Davies M, ‘Type 2 Diabetes: Recent Advances in Diagnosis and Management’ (2015) 26 Prescriber 15
Chimen M and others, ‘What Are the Health Benefits of Physical Activity in Type 1 Diabetes Mellitus? A Literature Review’ (2012) 55 Diabetologia 542
Choudhary P and others, ‘Islet Cell Transplantation: Current Status in the UK (2012)’ (2012) 29 Practical Diabetes 280
Copeland KC and others, ‘Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescents’ (2013) 131 PEDIATRICS 364
Courtney H and others, ‘Long-Term Management of Type 2 Diabetes with Glucagon-like Peptide-1 Receptor Agonists’ (2017) Volume 10 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 79
Crasto W, Jarvis J and Davies MJ, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
——, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
——, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
——, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
——, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
——, Handbook of Insulin Therapies (Adis 2016) <http://le.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=5664687440002746&institutionId=2746&customerId=2745>
Daly H and others, ‘Development of a Self-Management Education Module for Those with Type 2 Diabetes on Injectable Therapies’ (2015) 32 Practical Diabetes 305
Davies M and others, ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine’ (2005) 28 Diabetes Care 1282
——, ‘Introduction of Biosimilar Insulins in Europe’ (2017) 34 Diabetic Medicine 1340
Davies MJ and others, ‘Effectiveness of the Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) Programme for People with Newly Diagnosed Type 2 Diabetes: Cluster Randomised Controlled Trial’ (2008) 336 BMJ 491
Davies MJ and Chatterjee S, ‘Trial Watch: Insulin Initiation for Type 2 Diabetes Mellitus in Primary Care’ (2017) 13 Nature Reviews Endocrinology 317
Deacon CF and Lebovitz HE, ‘Comparative Review of Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas’ (2016) 18 Diabetes, Obesity and Metabolism 333
Dhatariya KK, Skedgel C and Fordham R, ‘The Cost of Treating Diabetic Ketoacidosis in the UK: A National Survey of Hospital Resource Use’ (2017) 34 Diabetic Medicine 1361
Diamant M and others, ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’ (2010) 375 The Lancet 2234
——, ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’ (2010) 375 The Lancet 2234
Dungan KM and others, ‘Once-Weekly Dulaglutide versus Once-Daily Liraglutide in Metformin-Treated Patients with Type 2 Diabetes (AWARD-6): A Randomised, Open-Label, Phase 3, Non-Inferiority Trial’ (2014) 384 The Lancet 1349
‘Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomised Controlled Trials- ClinicalKey’ <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858717301043?returnurl=null&referrer=null>
‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 1799
Evans M and others, ‘A Review of Modern Insulin Analogue Pharmacokinetic and Pharmacodynamic Profiles in Type 2 Diabetes: Improvements and Limitations’ (2011) 13 Diabetes, Obesity and Metabolism 677
Frandsen CSS and Madsbad S, ‘Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors as an Add-on to Insulin Treatment in Patients with Type 2 Diabetes: A Review’ (2014) 31 Diabetic Medicine 1293
Funnell MM, ‘Overcoming Barriers to the Initiation of Insulin Therapy’ (2007) 25 Clinical Diabetes 36
Gallwitz B and others, ‘2-Year Efficacy and Safety of Linagliptin Compared with Glimepiride in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Randomised, Double-Blind, Non-Inferiority Trial’ (2012) 380 The Lancet 475
Garber AJ and others, ‘Attainment of Glycaemic Goals in Type 2 Diabetes with Once-, Twice-, or Thrice-Daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study)’ (2006) 8 Diabetes, Obesity and Metabolism 58
Garber AJ and others, ‘Premixed Insulin Treatment for Type 2 Diabetes: Analogue or Human?’ (2007) 9 Diabetes, Obesity and Metabolism 630
Garber AJ and others, ‘Insulin Degludec, an Ultra-Longacting Basal Insulin, versus Insulin Glargine in Basal-Bolus Treatment with Mealtime Insulin Aspart in Type 2 Diabetes (BEGIN Basal-Bolus Type 2): A Phase 3, Randomised, Open-Label, Treat-to-Target Non-Inferiority Trial’ (2012) 379 The Lancet 1498
Gough SCL, ‘A Review of Human and Analogue Insulin Trials’ (2007) 77 Diabetes Research and Clinical Practice 1
Gough SCL and others, ‘Insulin Degludec: Overview of a Novel Ultra Long-Acting Basal Insulin’ (2013) 15 Diabetes, Obesity and Metabolism 301
Grammes J and others, ‘Focus Group Study to Identify the Central Facets of Fear of Hypoglycaemia in People with Type 2 Diabetes Mellitus’ [2017] Diabetic Medicine
Gray LJ and others, ‘Implementation of the Automated Leicester Practice Risk Score in Two Diabetes Prevention Trials Provides a High Yield of People with Abnormal Glucose Tolerance’ (2012) 55 Diabetologia 3238
Gray LJ and others, ‘External Validation of Two Diabetes Risk Scores in a Young UK South Asian Population’ (2014) 104 Diabetes Research and Clinical Practice 451
Green JB and others, ‘Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes’ (2015) 373 New England Journal of Medicine 232
Gururaj Setty S and others, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’ (2016) 92 Postgraduate Medical Journal 152
——, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’ (2016) 92 Postgraduate Medical Journal 152
Hadjiconstantinou M and others, ‘Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis’ (2016) 18 Journal of Medical Internet Research
Hartman YAW and others, ‘Insulin-Associated Weight Gain in Type 2 Diabetes Is Associated With Increases in Sedentary Behavior’ (2017) 40 Diabetes Care e120
Heinonen I and others, ‘Sedentary Behaviours and Obesity in Adults: The Cardiovascular Risk in Young Finns Study’ (2013) 3 BMJ Open
Heller SR and others, ‘Hypoglycaemia with Insulin Aspart: A Double-Blind, Randomised, Crossover Trial in Subjects with Type 1 Diabetes’ (2004) 21 Diabetic Medicine 769
Henson, Joseph, ‘Associations of Sedentary Time with Fat Distribution in a High-Risk Population.’ <https://lra.le.ac.uk/handle/2381/32505>
Hermansen K and others, ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’ (2006) 29 Diabetes Care 1269
Holman RR and others, ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’ (2007) 357 New England Journal of Medicine 1716
Holman RR and Turner RC, ‘A Practical Guide to Basal and Prandial Insulin Therapy’ (1985) 2 Diabetic Medicine 45
Home PD, ‘The Pharmacokinetics and Pharmacodynamics of Rapid-Acting Insulin Analogues and Their Clinical Consequences’ (2012) 14 Diabetes, Obesity and Metabolism 780
Horvath K and others, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>
——, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>
Htike ZZ and others, ‘Glucagon like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Management of Type 2 Diabetes: Choosing the Right Agent for Individualised Care’ (2016) 16 British Journal of Diabetes
Htike ZZ and others, ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’ (2017) 19 Diabetes, Obesity and Metabolism 524
——, ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’ (2017) 19 Diabetes, Obesity and Metabolism 524
Inzucchi SE and others, ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’ (2015) 38 Diabetes Care 140
Ismail-Beigi F, ‘Glycemic Management of Type 2 Diabetes Mellitus’ (2012) 366 New England Journal of Medicine 1319
John M Jakicic, ‘Physical Activity Considerations for the Treatment and Prevention of Obesity’ (2005) 82 The American Journal of Clinical Nutrition 226S <http://ajcn.nutrition.org/content/82/1/226S>
Johnston BC and others, ‘Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults’ (2014) 312 JAMA
Jones AG and Hattersley AT, ‘The Clinical Utility of C-Peptide Measurement in the Care of Patients with Diabetes’ (2013) 30 Diabetic Medicine 803
Kamlesh Khunti, ‘Systematic Review and Meta-Analysis of Response Rates and Diagnostic Yield of Screening for Type 2 Diabetes and Those at High Risk of Diabetes’ (2015) 10 PLoS ONE <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556656/?report=classic>
Kenneth Hodson, ‘Gestational Diabetes: Emerging Concepts in Pathophysiology’ (2010) 3 Obstetric Medicine <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989628/?report=classic>
Latika Sahu, ‘Comparison of the American Diabetes Association and World Health Organization Criteria for Gestational Diabetes Mellitus and the Outcomes of Pregnancy’ (2009) 2 Obstetric Medicine <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4989660/?report=classic>
Lee I-M, ‘Physical Activity and Weight Gain Prevention’ (2010) 303 JAMA
Leff DR and Heath D, ‘Surgery for Obesity in Adulthood’ (2009) 339 BMJ b3402
Levin PA and others, ‘Glucagon-like Peptide-1 Receptor Agonists: A Systematic Review of Comparative Effectiveness Research’ (2017) Volume 10 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 123
‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 1797
Mäkimattila S, Nikkilä K and Yki-Järvinen H, ‘Causes of Weight Gain during Insulin Therapy with and without Metformin in Patients with Type II Diabetes Mellitus’ (1999) 42 Diabetologia 406
Marre M and others, ‘Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (LEAD-1 SU)’ (2009) 26 Diabetic Medicine 268
Marso SP and others, ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 311
——, ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 311
——, ‘Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 1834
Merlin C. Thomas, ‘Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment’ (2016) 7 Diabetes Therapy <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014795/>
Michael Riddell, ‘Exercise and Glucose Metabolism in Persons with Diabetes Mellitus: Perspectives on the Role for Continuous Glucose Monitoring’ (2009) 3 Journal of diabetes science and technology (Online) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769951/>
Min SH and others, ‘Comparison between SGLT2 Inhibitors and DPP4 Inhibitors Added to Insulin Therapy in Type 2 Diabetes: A Systematic Review with Indirect Comparison Meta-Analysis’ (2017) 33 Diabetes/Metabolism Research and Reviews
‘Minimizing Hypoglycemia in Diabetes: Table 1’ (2015) 38 Diabetes Care 1583
Mishriky BM, Cummings DM and Tanenberg RJ, ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’ (2015) 109 Diabetes Research and Clinical Practice 378
——, ‘The Efficacy and Safety of DPP4 Inhibitors Compared to Sulfonylureas as Add-on Therapy to Metformin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis’ (2015) 109 Diabetes Research and Clinical Practice 378
Moreno-Castilla C, Mauricio D and Hernandez M, ‘Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus’ (2016) 16 Current Diabetes Reports
Nathan DM and others, ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes’ (2006) 29 Diabetes Care 1963
Nauck M, ‘Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors’ (2016) 18 Diabetes, Obesity and Metabolism 203
Nauck M and others, ‘Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)’ (2014) 37 Diabetes Care 2149
Nauck MA and others, ‘Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Compared with the Sulfonylurea, Glipizide, in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone: A Randomized, Double-Blind, Non-Inferiority Trial’ (2007) 9 Diabetes, Obesity and Metabolism 194
Nauck MA and Meier JJ, ‘The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Interventions’ (2016) 4 The Lancet Diabetes & Endocrinology 525
Nissen SE and Wolski K, ‘Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes’ (2007) 356 New England Journal of Medicine 2457
Nolan CJ and others, ‘Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes’ (2015) 64 Diabetes 673
Paul Craddy, ‘Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison’ (2014) 5 Diabetes Therapy <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065303/>
Persaud SJ and Jones PM, ‘A Wake-up Call for Type 2 Diabetes?’ (2016) 375 New England Journal of Medicine 1090
‘Postnatal Testing Following Gestational Diabetes- ClinicalKey’ <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2213858715003228?returnurl=null&referrer=null>
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’ <https://www.youtube.com/watch?v=AhhWTmEFuag>
Qin L and others, ‘Does Physical Activity Modify the Risk of Obesity for Type 2 Diabetes: A Review of Epidemiological Data’ (2010) 25 European Journal of Epidemiology 5
Raskin P and others, ‘Initiating Insulin Therapy in Type 2 Diabetes: A Comparison of Biphasic and Basal Insulin Analogs’ (2005) 28 Diabetes Care 260
‘Resources and Tools’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html>
‘——’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/79:global-guideline-for-type-2-diabetes.html>
‘——’ <http://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/80:the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html>
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes (John Wiley 2016) <https://ebookcentral-proquest-com.ezproxy4.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056>
Richter B and Neises G, ‘“Human” Insulin versus Animal Insulin in People with Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>
Riddle MC and others, ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)’ (2013) 36 Diabetes Care 2489
Rinki Murphy, ‘Monogenic Diabetes and Pregnancy’ (2015) 8 Obstetric Medicine <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935018/>
Rizos CV, Kei A and Elisaf MS, ‘The Current Role of Thiazolidinediones in Diabetes Management’ (2016) 90 Archives of Toxicology 1861
Rosenstock J and others, ‘A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-on to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes’ (2008) 51 Diabetologia 408
——, ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized, Open-Label, Active-Controlled Study (GetGoal-X)’ (2013) 36 Diabetes Care 2945
Rotz ME and others, ‘Implications of Incretin-Based Therapies on Cardiovascular Disease’ (2015) 69 International Journal of Clinical Practice 531
Ryder B and others, ‘ABCD Position Statement on GLP-1 Based Therapies and Pancreatic Damage’ (2013) 30 Practical Diabetes 388
S M Attard, ‘Implications of Iron Deficiency/Anemia on the Classification of Diabetes Using HbA1c’ (2015) 5 Nutrition & Diabetes <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491857/>
‘Safety and Insulin: Implementation of National Guidance at a Local Level | Journal Content | Diabetesonthenet.Com’ <http://www.diabetesonthenet.com/journal-content/view/safety-and-insulin-implementation-of-national-guidance-at-a-local-level>
Sallis JF and others, ‘Progress in Physical Activity over the Olympic Quadrennium’ (2016) 388 The Lancet 1325
Samuel VT and Shulman GI, ‘Intergrating Mechanisms for Insulin Resistance: Common Threads and Missing Links’ (2012) 148 Cell 852
Schauer PR and others, ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’ (2012) 366 New England Journal of Medicine 1567
——, ‘Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes’ (2012) 366 New England Journal of Medicine 1567
——, ‘Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes’ (2017) 376 New England Journal of Medicine 641
Schwartz SS and others, ‘The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema’ (2016) 39 Diabetes Care 179
Simmons RK and others, ‘A Randomised Trial of the Effect and Cost-Effectiveness of Early Intensive Multifactorial Therapy on 5-Year Cardiovascular Outcomes in Individuals with Screen-Detected Type 2 Diabetes: The Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) Study’ (2016) 20 Health Technology Assessment 1
Sivasubramaniyam S, Amiel SA and Choudhary P, ‘Proportion of Daily Capillary Blood Glucose Readings Required in the Target Range for Target Glycaemic Control: Shift of Focus from Target Range to Proportion in Range’ (2017) 34 Diabetic Medicine 1456
Sjöström L and others, ‘Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery’ (2004) 351 New England Journal of Medicine 2683
Srinivasan BT and others, ‘Recent Advances in the Management of Type 2 Diabetes Mellitus: A Review’ (2008) 84 Postgraduate Medical Journal 524
Srinivasan BT and Davies M, ‘Glycaemic Management of Type 2 Diabetes’ (2014) 42 Medicine 711
Srinivasan P and others, ‘Islet Cell Transplantation’ (2007) 83 Postgraduate Medical Journal 224
‘Standards of Medical Care in Diabetes--2015: Summary of Revisions’ (2015) 38 Diabetes Care S4
Steven S and others, ‘Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders’ (2016) 39 Diabetes Care 808
Steven S and Taylor R, ‘Restoring Normoglycaemia by Use of a Very Low Calorie Diet in Long- and Short-Duration Type 2 Diabetes’ (2015) 32 Diabetic Medicine 1149
Stewart ZA and others, ‘Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes’ (2016) 375 New England Journal of Medicine 644
Swinnen SG and others, ‘Insulin Detemir versus Insulin Glargine for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>
Tanner M, ‘Review: In Type 2 Diabetes, Adding Dipeptidyl Peptidase-4 Inhibitors to Sulphonylureas Increases Hypoglycemia’ (2016) 165 Annals of Internal Medicine
Tao L and others, ‘Cost-Effectiveness of Intensive Multifactorial Treatment Compared with Routine Care for Individuals with Screen-Detected Type 2 Diabetes: Analysis of the ADDITION-UK Cluster-Randomized Controlled Trial’ (2015) 32 Diabetic Medicine 907
‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’ <https://www.nice.org.uk/guidance/ng28>
Umpierre D, ‘Physical Activity Advice Only or Structured Exercise Training and Association With HbA Levels in Type 2 Diabetes’ (2011) 305 JAMA
‘Unit 3 – Special Care Groups: A Practical Guide to Pregnancy Complicated by Diabetes - Diabetes & Primary Care’ <http://www.diabetesandprimarycare.co.uk/journal-content/view/unit-3-special-care-groups-a-practical-guide-to-pregnancy-complicated-by-diabetes/?preview>
Villani M, de Courten B and Zoungas S, ‘Emergency Treatment of Hypoglycaemia: A Guideline and Evidence Review’ (2017) 34 Diabetic Medicine 1205
Vloemans AF and others, ‘Keeping Safe. Continuous Glucose Monitoring (CGM) in Persons with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia: A Qualitative Study’ (2017) 34 Diabetic Medicine 1470
Wanner C and others, ‘Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes’ (2016) 375 New England Journal of Medicine 323
‘WHO 2011 Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus’ <http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/>
Yeh JS, Kushner RF and Schiff GD, ‘Obesity and Management of Weight Loss’ (2016) 375 New England Journal of Medicine 1187
Yki-Järvinen H and others, ‘Insulin Glargine or NPH Combined with Metformin in Type 2 Diabetes: The LANMET Study’ (2006) 49 Diabetologia 442
Young LA and Buse JB, ‘GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes’ (2014) 384 The Lancet 2180
Young-Hyman D and others, ‘Erratum. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140’ (2017) 40 Diabetes Care 287.1
Zaccardi F and others, ‘Pathophysiology of Type 1 and Type 2 Diabetes Mellitus: A 90-Year Perspective’ (2016) 92 Postgraduate Medical Journal 63
Zinman B and others, ‘Insulin Degludec, an Ultra-Long-Acting Basal Insulin, Once a Day or Three Times a Week versus Insulin Glargine Once a Day in Patients with Type 2 Diabetes: A 16-Week, Randomised, Open-Label, Phase 2 Trial’ (2011) 377 The Lancet 924
